Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporatio (EW) reported trailing twelve months (TTM) revenue of $6.07B as of December 2025, which represents a 11.5% increase year-over-year. The company's operating margin has expanded to 31.0% from 27.5% a year ago. In terms of profitability, EW generated $1.07B in net income. Valuation-wise, the stock trades at a P/E ratio of 46.6x and a Price-to-Sales (P/S) ratio of 8.2x. The company generated $715.60M in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.
Quarterly standardized metrics.
Stock price and market valuation
Top-line sales performance
EBITDA and Net Income trends
Price-to-earnings and price-to-sales ratios
Free cash flow generation
Operating and net margin percentages
